A long-lasting, single-dose nasal vaccine for Ebola: A practical armament for an outbreak with significant global impact

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 5, 2015, Pages 527-530

  Jonsson Schmunk, Kristina ^a   Croyle, Maria A ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

VSV

Indexed keywords

EBOLA VACCINE;

DEVELOPING COUNTRY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; EPIDEMIC; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INDUSTRIALIZATION; INFECTION PREVENTION; NONHUMAN; PATIENT COMPLIANCE; REVIEW; SINGLE DRUG DOSE; EBOLAVIRUS; HEALTH; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; PATHOGENICITY; PROCEDURES;

ADMINISTRATION, INTRANASAL; EBOLA VACCINES; EBOLAVIRUS; GLOBAL HEALTH; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 84927624495     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.1028368     Document Type: Review

References (38)

1. Maŕi Saez A, Weiss S, Nowak K, et al. Investigating the Zoonotic Origin of the West African Ebola Epidemic. EMBO Mol Med 2014;7(1):17-23
2. Maurice J. WHO. Meeting Chooses Untried Interventions to Defeat Ebola. Lancet 2014;384(9948):e45-6
3. Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee Adenovirus Vaccine Generates Acute and Durable Protective Immunity Against Ebolavirus Challenge. Nat Med 2014;20(10):1126-9
4. Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee Adenovirus Vector Ebola Vaccine-Preliminary Report. N Engl J Med 2014. [Epub ahead of print]
5. Rampling T, Ewer K, Bowyer G, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine-Preliminary Report. N Engl J Med 2015; [Epub ahead of print]
6. Choi JH, Croyle MA. Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs 2013;27(6):565-83
7. Gunther S, Feldmann H, Geisbert TW, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 2011;204(Suppl 3):S785-90
8. Lyford J. Ebola clinical trial suspended after volunteers complain of joint pains. In: The Pharmaceutical Journal. (Accessed on 2014. Available from: www.pharmaceutical-journal.com/news-and-analysis/news/ebola-clinical-trial-suspended-after-volunteers-complain-of-joint-pains/20067418.article
9. National Institute of Allergy and Infectious Diseases (NIAID). National Institutes of Health Clinical Center (CC). Partnership for Research on Ebola Vaccines in Liberia (PREVAIL). In:ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000. Accessed on 2015. Available from: http://clinicaltrials.gov/show study/NCT02344407 NLM Identifier: NCT02344407
10. Kochhar S, Rath B, Seeber LD, et al. Vienna Vaccine Safety Initiative. Introducing New Vaccines in Developing Countries. Expert Rev Vaccines 2013; 12(12):1465-78
11. Del Rio C, Mehta AK, Lyon GM, Guarner J. Ebola Hemorrhagic Fever In 2014: the Tale Of An Evolving Epidemic. Ann Intern Med 2014;161(10):746-8
12. Marzi A, Feldmann H. Ebola Virus Vaccines: an Overview of Current Approaches. Expert Rev Vaccines 2014; 13(4):521-31
13. Choi JH, Schafer SC, Zhang L, et al. Modeling Pre-Existing Immunity to Adenovirus in Rodents: immunological Requirements for Successful Development of a Recombinant Adenovirus Serotype 5-Based Ebola Vaccine. Mol Pharm 2013;3(10):3342-55
14. Wong G, Richardson JS, Pillet S, et al. Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates. Sci Transl Med 2012;4(158):158ra146
15. Sullivan NJ, Hensley L, Asiedu C, et al. CD8+ Cellular Immunity Mediates rAd5 Vaccine Protection against Ebola Virus Infection of Nonhuman Primates. Nat Med 2011;17(9):1128-31
16. Richardson JS, Pillet S, Bello AJ, Kobinger GP. Airway Delivery of an Adenovirus-Based Ebola Virus Vaccine Bypasses Existing Immunity to Homologous Adenovirus in Nonhuman Primates. J Virol 2013;87(7):3668-77
17. Choi JH, Jonsson-Schmunk K, Qiu X, et al. A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection. Mol Pharm 2014; [Epub ahead of print]
18. Wong G, Audet J, Fernando L, et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 2014;32(43):5722-9
19. Ducusin J, Narvaez D, Wilburn S, et al. Waste Management and Disposal During the Philippine Follow-Up Measles Campaign. Health Care without Harm and the Philippine Department of Health, Washington, D.C., U.S.A. and Manilla, Phillipines, 2004. 1-112
20. Rothe C, Schlaich C, Thompson S. Healthcare-Associated Infections in Sub-Saharan Africa. J Hosp Infect 2013; 85(4):257-67
21. Djupesland PG. Nasal Drug Delivery Devices: characteristics and Performance in a Clinical Perspective-A Review. Drug Deliv. Transl Res 2013;3(1):42-62
22. Fields BN, Hawkins K. Human Infection with the Virus of Vesicular Stomatitis During an Epizootic. N Engl J Med 1967; 277(19):989-94
23. Lion T. Adenovirus Infections in Immunocompetent and Immunocompromised Patients. Clin Microbiol Rev 2014;27(3):441-62
24. Riese P, Sakthivel P, Trittel S, Guzmán CA. Intranasal Formulations: promising Strategy to Deliver Vaccines. Expert Opin. Drug Deliv 2014;11(10):1619-34
25. Djupesland PG, Messina JC, Mahmoud RA. The Nasal Approach to Delivering Treatment for Brain Diseases: an Anatomic, Physiologic, and Delivery Technology Overview. Ther Deliv 2014;5(6):709-33
26. Mire CE, Miller AD, Carville A, et al. Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates. PLoS Negl Trop Dis 2012;6(3):e1567
27. Damjanovic D, Zhang X, Mu J, et al. Organ Distribution of Transgene Expression Following Intranasal Mucosal Delivery of Recombinant Replication-Defective Adenovirus Gene Transfer Vector. Genet Vaccines Ther 2008;6:5
28. Gau P, Rodriguez S, De Leonardis C, et al. Air-assisted intranasal instillation enhances adenoviral delivery to the olfactory epithelium and respiratory tract. Gene Ther 2011;18(5):432-6
29. Levine MM, Robins-Browne R. Vaccines, Global Health and Social Equity. Immunol Cell Biol 2009;87(4):274-8
30. Matthias DM, Robertson J, Garrison MM, et al. Freezing Temperatures in the Vaccine Cold Chain: A Systematic Literature Review. Vaccine 2007;25(20):3980-6
31. Chen D, Kristensen D. Opportunities and Challenges of Developing Thermostable Vaccines. Expert Rev Vaccines 2009;8(5): 547-57
32. WHO Virtual Press Conference Following the Second High-Level Meeting on Ebola Vaccines Access and Financing. World Health Organization, Geneva, Switzerland, 2015
33. Renteria SS, Clemens CC, Croyle MA. Development of a Nasal Adenovirus-Based Vaccine: Effect of Concentration and Formulation on Adenovirus Stability and Infectious Titer During Actuation From Two Delivery Devices. Vaccine 2010;28(9): 2137-48
34. Croyle MA, Cheng X, Wilson JM. Development of Formulations That Enhance Physical Stability of Viral Vectors for Gene Therapy. Gene Ther 2001;8(17): 1281-90
35. Zimmer B, Summermatter K, Zimmer G. Stability and Inactivation of Vesicular Stomatitis Virus, a Prototype Rhabdovirus. Vet Microbiol 2013;162(1):78-84
36. 2014; Ebola Outbreak in West Africa. 2014. Accessed on 2015. Centers for Disese Control and Prevention: Atlanta, GA. Available from: www.cdc.gov/vhf/ebola/outbreaks/guinea/index.html
37. Levine MM. "IDEAL" Vaccines for Resource Poor Settings. Vaccine 2011; 29(Suppl 4):D116-25
38. Milligan GN, Barrett AD. The Regulatory Path to Vaccine Licensure. In: Vaccinology: An Essential Guide. (Wiley Blackwell, Hoboken, NJ, 2015